Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-hydroxyoleic acid adjuvant trial in newly diagnosed primary glioblastoma
2018-000365-37Phase 2Active
- Sponsor
- Lipopharma Therapeutics
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing 2-hydroxyoleic acid + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Progression-free survival. Started Apr 2019; status: active.
02
Drugs
2-hydroxyoleic acid
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2018-000365-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000365-37.